New Corporate Connect flash note
We’re pleased to share a copy of a flash note by Corporate Connect following our announcement today on new interim paxalisib data from our phase II trial in glioblastoma, which is being presented at the Society for Neuro-Oncology (SNO) Annual Meeting.
The note says the data “are as ‘positive’ for efficacy as possible, given the trial’s single arm nature” and “withpositive phase II results in hand, paxalisib’s development for GBM will not skip a beat as it commences GBM AGILE.”
Corporate Connect research analyst Marc Sinatra also notes that: "We see things coming together very well for paxalisib … we will see the first interim analysis from the breast cancer brain metastases study before CY end. A hint of signal and Kazia will look appealing to deep pocked investors, with the larger drug companies close behind, given paxalisib’s owner could dictate the brain cancer space for years.”
Mr Sinatra retained his 12-month price target on Kazia of $2.05.
You can read a copy of the report here and the ASX Announcement on the data here.
Investor Conference Call on new paxalisib data
A reminder that Kazia will be holding a conference call tomorrow, Thursday 19 November 2020 at 12:00pm, Sydney time (AEDT) to discuss the new paxalisib data presented at the Society for Neuro-Oncology (SNO) Annual Meeting.
Participants will need to pre-register for the call via the following link: https://s1.c-conf.com/diamondpass/10011029-8iqiBr.html
KZA Price at posting:
$1.57 Sentiment: Buy Disclosure: Held
